Cobicistat

證據等級: L5

預測適應症: 3 個

Cobicistat: From HIV Pharmacokinetic Boosting to Simian Immunodeficiency Virus Infection

One-Sentence Summary

Cobicistat is not itself an antiviral agent — it is a pharmacokinetic booster (CYP3A4/CYP2D6, P-gp, and OATP1B1/1B3 inhibitor) co-formulated with antiretroviral drugs such as elvitegravir and atazanavir for HIV treatment. The TxGNN model predicts it may be relevant to Simian Immunodeficiency Virus (SIV) Infection, but this prediction is currently supported by 0 clinical trials and 0 publications, and rests entirely on graph-embedding similarity to HIV-related nodes.

Quick Overview

Item	Content
Original Indication	No approved indication text available — cobicistat is not marketed in Finland; globally known as a pharmacokinetic booster used alongside antiretroviral agents (no direct antiviral activity of its own)
Predicted New Indication	Simian Immunodeficiency Virus Infection
TxGNN Prediction Score	99.92%
Evidence Level	L5
Finland Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is flagged as a data gap in the evidence pack. Based on available pharmacological knowledge, cobicistat is a structural analog of ritonavir and acts as a potent inhibitor of CYP3A4/CYP2D6 and the transporters P-gp and OATP1B1/1B3. Its clinical role is to raise plasma concentrations of co-administered antiretrovirals rather than to exert direct antiviral effect.

SIV is a lentivirus infecting non-human primates and is taxonomically related to HIV, which likely explains why the TxGNN knowledge graph places cobicistat close to SIV-infection nodes — both share proximity to HIV/lentivirus-related entities in the embedding space. However, this is a topological similarity, not a demonstrated pharmacological one: cobicistat has no known direct antiviral activity against SIV or HIV itself, and SIV infection is a veterinary/animal-model disease rather than a human clinical indication.

The two other TxGNN candidates in this pack reinforce the same caution: feline immunodeficiency syndrome (rank 2) is likewise a veterinary lentivirus condition inferred purely from retrovirus homology, and the rare neurodevelopmental white-matter disorder (rank 3) has no plausible mechanistic link to cobicistat's known CYP/transporter-inhibition profile. All three predictions score similarly high (~99.9%) yet have zero supporting trials or literature — consistent with a graph-embedding artifact rather than a validated repurposing signal.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Finland Market Information

Cobicistat holds no marketing authorization in Finland (market status: not marketed; 0 authorizations on record), so no product/dosage-form information is available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: All three TxGNN-predicted indications (SIV infection, feline immunodeficiency syndrome, and a rare neurodevelopmental disorder) are Evidence Level L5 — model prediction only, with no supporting clinical trials or literature — and two of the three target animal, not human, diseases. Combined with a Blocking data gap on TFDA/Fimea package-insert safety data (DG001), this candidate cannot proceed past initial screening (S0).

To proceed, the following is needed:

TFDA/Fimea package insert data (warnings, contraindications) to clear the Blocking gap (DG001) before any S1 safety review
Confirmed mechanism-of-action data from DrugBank (DG002)
Independent pharmacological or preclinical evidence connecting cobicistat's CYP3A4/P-gp/OATP inhibition to a human-relevant indication, since the current top predictions are non-human disease models
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.